Berliner Boersenzeitung - SciBase and Skin and Cancer Institute partner to advance AI-driven skin cancer detection in California

EUR -
AED 3.999906
AFN 76.797516
ALL 101.247602
AMD 438.743527
ANG 1.963666
AOA 906.268709
ARS 394.499124
AUD 1.633816
AWG 1.9634
AZN 1.856075
BAM 1.955548
BBD 2.200017
BDT 120.124538
BGN 1.958177
BHD 0.412308
BIF 3098.95834
BMD 1.089265
BND 1.456812
BOB 7.5291
BRL 5.31627
BSD 1.08956
BTN 90.736154
BWP 14.744102
BYN 3.589838
BYR 21349.589966
BZD 2.196317
CAD 1.470236
CDF 2908.337395
CHF 0.947735
CLF 0.033918
CLP 935.907635
CNY 7.703503
COP 4318.107068
CRC 576.601961
CUC 1.089265
CUP 28.865517
CVE 110.564621
CZK 24.294204
DJF 193.584568
DKK 7.461142
DOP 61.925132
DZD 146.942917
EGP 33.776257
ERN 16.338972
ETB 60.676271
FJD 2.419044
FKP 0.861997
GBP 0.857756
GEL 2.935612
GGP 0.861997
GHS 13.071565
GIP 0.861997
GMD 73.311718
GNF 9373.123941
GTQ 8.534549
GYD 227.960658
HKD 8.509283
HNL 26.909024
HRK 7.670134
HTG 144.211438
HUF 379.086356
IDR 16788.45703
ILS 4.048988
IMP 0.861997
INR 90.647364
IQD 1426.93688
IRR 46035.057524
ISK 151.223052
JEP 0.861997
JMD 168.391369
JOD 0.772729
JPY 159.920454
KES 166.930249
KGS 97.14663
KHR 4486.682069
KMF 491.74901
KPW 980.276955
KRW 1410.418223
KWD 0.336289
KYD 0.907983
KZT 502.864499
LAK 22547.78162
LBP 16385.156917
LKR 357.68396
LRD 204.945587
LSL 20.391453
LTL 3.216316
LVL 0.658886
LYD 5.244853
MAD 10.980338
MDL 19.340688
MGA 4901.691952
MKD 61.61207
MMK 2288.205471
MNT 3760.199955
MOP 8.769371
MRO 388.867344
MUR 48.352877
MVR 16.731519
MWK 1834.870618
MXN 18.72098
MYR 5.090177
MZN 68.895944
NAD 20.271629
NGN 859.430297
NIO 40.046862
NOK 11.701792
NPR 145.177646
NZD 1.754615
OMR 0.421215
PAB 1.089615
PEN 4.072803
PGK 4.06721
PHP 60.290266
PKR 310.685593
PLN 4.328761
PYG 8106.621645
QAR 3.965741
RON 4.957286
RSD 117.363212
RUB 99.368223
RWF 1357.223934
SAR 4.086048
SBD 9.232549
SCR 14.634947
SDG 654.648511
SEK 11.362976
SGD 1.452648
SHP 1.325363
SLE 24.762839
SLL 21512.980054
SOS 622.518821
SRD 41.191097
STD 22545.582023
SYP 14161.522499
SZL 20.39144
THB 37.983066
TJS 11.914374
TMT 3.823319
TND 3.390923
TOP 2.5686
TRY 31.479539
TTD 7.392116
TWD 34.049369
TZS 2739.501323
UAH 39.735485
UGX 4143.46667
USD 1.089265
UYU 42.604516
UZS 13403.403657
VEF 3860142.930966
VES 38.634829
VND 26469.134499
VUV 129.846293
WST 2.977169
XAF 655.872579
XAG 0.042742
XAU 0.000526
XCD 2.943793
XDR 0.818695
XOF 654.648503
XPF 119.656134
YER 272.697837
ZAR 20.324378
ZMK 9804.694177
ZMW 25.878907
ZWL 350.742819
  • SCU

    -0.0300

    12.72

    -0.24%

  • NGG

    0.8300

    66.84

    +1.24%

  • BCE

    0.9200

    40.31

    +2.28%

  • SCS

    0.1500

    12.46

    +1.2%

  • BCC

    3.0900

    112.39

    +2.75%

  • RIO

    2.0700

    71.16

    +2.91%

  • RYCEF

    0.1043

    3.53

    +2.95%

  • RBGPF

    0.3720

    68.01

    +0.55%

  • SLAC

    0.0390

    10.29

    +0.38%

  • CMSC

    0.0600

    24.61

    +0.24%

  • RELX

    -0.0200

    38.56

    -0.05%

  • GSK

    0.5800

    36.57

    +1.59%

  • BTI

    0.1500

    32.04

    +0.47%

  • AZN

    0.2000

    64.79

    +0.31%

  • BP

    -0.3100

    35.98

    -0.86%

  • JRI

    0.2100

    11.28

    +1.86%

  • CMSD

    0.1800

    24.33

    +0.74%

  • VOD

    0.1600

    9.22

    +1.74%

SciBase and Skin and Cancer Institute partner to advance AI-driven skin cancer detection in California
SciBase and Skin and Cancer Institute partner to advance AI-driven skin cancer detection in California

SciBase and Skin and Cancer Institute partner to advance AI-driven skin cancer detection in California

STOCKHOLM, Nov. 16, 2023 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO:SCIB)a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement with the Skin and Cancer Institute to pilot Nevisense in several of their California locations. The Skin and Cancer Institute is a world-renowned dermatology practice group of dermatologists and skin cancer surgeons, and will be the first dermatology practice group in California to bring AI-driven technology to their patients for skin cancer detection. With more than 50 offices across a three-state network comprised of California, Arizona and Nevada, they are one of the largest dermatology groups in the country. The collaboration will provide the Skin and Cancer Institute's group with Nevisense, the only AI-driven FDA approved test for early melanoma detection at point-of-care.

Text size:

"We are excited to integrate the Nevisense test during routine skin exams in several of our California offices and offer our patients the latest AI-driven technology for the earliest possible detection of melanoma.  Melanoma is the deadliest form of skin cancer, but when detected early, treatment has a nearly 100% cure rate.  Early testing and treatment are critical for improving survival rates.  We are committed to providing life-saving treatments to our patients and strive to deliver the highest level of care possible. For these reasons, we want to provide our patients with the most advanced technology that further supports our commitment to delivering the best care to our patients," said Dr. Dan Taheri, Medical Director and CEO of The Skin Cancer Institute Dermatology Group.

"We are very pleased to announce our collaboration with the Skin and Cancer Institute. In addition to the early detection benefits for patients, the partnership means clinicians at several of their California offices will have access to state-of-the-art melanoma detection technology at point-of-care. For SciBase, this means we expand and establish a coast-to-coast reach that provides patients with access to early melanoma detection technology. It also helps introduce Nevisense to more US payers." said Pia Renaudin, Chief Executive Officer of SciBase.

For more information, please contact:

Pia Renaudin, CEO SciBase
Tel: +46 73 206 98 02
Email: [email protected]

Certified Advisor (CA):

Vator Securities
Tel: +46 8 580 065 99
Email: [email protected]

About SciBase and Nevisense
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.  All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases .

The following files are available for download:

https://mb.cision.com/Main/12371/3876877/2433993.pdf

SciBase and Skin and Cancer Institute partner to advance AI in California - eng final

(K.Lüdke--BBZ)